Blinatumomab-associated vasculitis

ALL: acute lymphoblastic leukemia INTRODUCTION Blinatumomab is the first-in-class bispecific T-cell engager antibody approved for the treatment of refractory acute lymphoblastic leukemia (ALL). It simultaneously binds endogenous CD3 cytotoxic T cells and CD19 B cells, resulting in T-celle mediated serial lysis of normal and malignant B cells. Although studies have been conducted into the incidence and severity of adverse events, cutaneous vasculitis has not been reported thus far.